LeMaitre Vascular (LMAT) stock
LMAT's Quality Score rose 1 point on Mon, Oct 5, to 4. Closed near the day's high.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Why LMAT scores 4
Below AverageTrending down, 3 of 14 checks firingWhat the Quality Score means
- +3Chart checks 3 of 14 firing right now, one point each
- −3Long-term trend below a falling 200-day average, down over one year, down over two years
- Profit adds
- Growth adds
What's next
Expected to report Thu Nov 5, after the close
After its last 4 reports it closed -0.3% on average, higher 2 of 4 times.
What would turn LMAT's score around: 5 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
LMAT has 3 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1447.9
- MACD (12, 26, 9)Above signal
- 50-day average$83.87
- 200-day average$94.59
- ADX 1417.4
- Support$79.39
- Resistance$81.82
- Bollinger Bands (20, 2)Inside
- Volume1.4x
How LMAT ranks in Medical Devices
LMAT is #52 of 84 by Quality Score. The top three are shown with their scores, and more by name.
BLFS10/1422
CBLL10/1418
HTFL9/1417
KMTSOpen for its score
LIVNOpen for its score
MDLNOpen for its score
MDTOpen for its score
LMAT3/144
When does LMAT report earnings, and what happens after?
Expected to report Thu Nov 5, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 4, 2026After close | After close | -16.7% | -25.3% | -21.7% |
| May 5, 2026After close | After close | +1.5% | -1.6% | -13.2% |
| Feb 25, 2026After close | After close | +11.6% | +24.4% | +16.4% |
| Nov 6, 2025After close | After close | -3.0% | +1.4% | +4.7% |
About LeMaitre Vascular
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of LMAT's score, with the points and the reason
- All 14 checks on LMAT and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on LMAT
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.